EQL Pharmas continues to expand its product portfolio and have today started selling its second product on the Swedish market, Metformin EQL Pharma.
Metformin belongs to the biguanide class of oral anti-diabetic drugs. It reduces blood glucose levels and is the first choice of therapy in type 2 diabetics when diet and excercise alone does not help the patients. The original product is Glucophage. Metformin EQL Pharma is available in three dosage forms: 500, 850 and 1000 mg coated tablets.
”Step by step we continue to build up the EQL Pharma product portfolio with the goal to become the most market driven generics and speciality pharma company in the Nordic region. The launch of our second product on the Swedish market, Metformin EQL Pharma, is an important event in our companys development”, says CEO Christer Fåhraeus.